Leroith Derek, Scheinman Eyal J, Bitton-Worms Keren
"Diabetes and Metabolism Clinical Research Center of Excellence", Legacy Heritage Clinical Research Institute at Rambam (LHCRIR), Haifa, Israel.
Rambam Maimonides Med J. 2011 Apr 30;2(2):e0043. doi: 10.5041/RMMJ.10043. Print 2011 Apr.
Patients with type 2 diabetes (T2D) are at increased risk of developing cancer. This evidence arises from numerous epidemiologic studies that relate a positive association between T2D and cancer. In-vitro and several in-vivo experiments have attempted to discern the potential mechanistic factors involved in this relationship. Candidates include hyperinsulinemia, insulin-like growth factor-1 (IGF-1), and insulin-like growth factor-2 (IGF-2) signaling. These studies demonstrated that increased insulin, IGF-1, and IGF-2 signaling through the insulin receptor and IGF-1 receptor can induce cancer development and progression.
2型糖尿病（T2D）患者患癌症的风险增加。这一证据来自众多流行病学研究，这些研究表明T2D与癌症之间存在正相关。体外和一些体内实验试图识别这种关系中潜在的机制因素。候选因素包括高胰岛素血症、胰岛素样生长因子-1（IGF-1）和胰岛素样生长因子-2（IGF-2）信号传导。这些研究表明，通过胰岛素受体和IGF-1受体增加的胰岛素、IGF-1和IGF-2信号传导可诱导癌症的发生和发展。
